secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001437749-26-007071
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma reports 2025 net loss $8.7M; PH-762 Phase 1b dose escalation complete with favorable data
--------------------------------------------------------------------------------

- Net loss of $8.7M ($1.45 EPS) for 2025 vs $7.2M ($9.08 EPS) in 2024; R&D expenses up 27%.
- Cash at Dec 31, 2025: $21.0M vs $5.4M year ago; net proceeds from 2025 financings of $20.6M extend runway into H1 2027.
- PH-762 Phase 1b dose escalation trial fully enrolled (22 patients); final cohort shows favorable safety, tolerability and pathology.
- FDA submission seeking guidance on next steps for PH-762 targeted for Q2 2026; patent portfolio includes 54 issued patents.
- Phio entered drug substance development agreement with US manufacturer and toxicology study agreement with US lab in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926007071/0001437749-26-007071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926007071/phio20251215_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-007071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer